drugset / Trial / NCT06745063
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
Phase 2
Recruiting
50 enrolled
VA Office of Research and Development
University of Missouri-Columbia · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
Timeline
- Start
- 2025-05-30
- Primary completion
- 2028-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | — |